Acacetin Prevents Bone Loss by Disrupting Osteoclast Formation and Promoting Type H Vessel Formation in Ovariectomy-Induced Osteoporosis

Osteoporosis, characterized by the destruction of bone resorption and bone formation, is a serious disease that endangers human health. Osteoporosis prevention and treatment has become one of the important research contents in the field of medicine. Acacetin, a natural flavonoid compound, could promote osteoblast differentiation, and inhibit osteoclast formation in vitro. However, the mechanisms of acacetin on osteoclast differentiation and type H vessel formation, as well as the effect of preventing bone loss, remain unclear. Here, we firstly used primary bone marrow derived macrophages (BMMs), endothelial progenitor cells (EPCs), and ovariectomized (OVX) mice to explore the function of acacetin on bone remodeling and H type vessel formation. In this study, we found that acacetin inhibits osteoclast formation and bone resorption of BMMs induced by the macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL) in a concentration of 20 μM without exerting cytotoxic effects. It was accompanied by downregulation of osteoclast differentiation marker genes (Ctsk, Acp5, and Mmp9) and cell fusion genes (CD9, CD47, Atp6v0d2, Dc-stamp, and Oc-stamp). Moreover, acacetin disrupted actin ring formation and extracellular acidification in osteoclasts. Mechanistic analysis revealed that acacetin not only inhibits the expression of the major transcription factor NFATc1 and NF-κB during RANKL-induced osteoclast formation, but also suppresses RANKL-induced the phosphorylation of Akt, GSK3β, IκBα, and p65. Additionally, acacetin enhanced the ability of M-CSF and RANKL-stimulated BMMs to promote angiogenesis and migration of EPCs. We further established that, in vivo, acacetin increased trabecular bone mass, decreased the number of osteoclasts, and showed more type H vessels in OVX mice. These data demonstrate that acacetin prevents OVX-induced bone loss in mice through inhibition of osteoclast function and promotion of type H vessel formation via Akt/GSK3β and NF-κB signalling pathway, suggesting that acacetin may be a novel therapeutic agent for the treatment of osteoporosis.

[1]  Hong-xia Fan,et al.  Celastrol Attenuates RANKL-Induced Osteoclastogenesis in vitro and Reduces Titanium Particle-Induced Osteolysis and Ovariectomy-Induced Bone Loss in vivo , 2021, Frontiers in Pharmacology.

[2]  Ying-Xing Xu,et al.  Icariin stimulates osteogenesis and suppresses adipogenesis of human bone mesenchymal stem cells via miR-23a-mediated activation of the Wnt/β-catenin signaling pathway. , 2021, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[3]  F. Caradonna,et al.  Flavonoids in Bone Erosive Diseases: Perspectives in Osteoporosis Treatment , 2020, Trends in endocrinology and metabolism.

[4]  S. Mani,et al.  Acacetin Ameliorates Experimental Colitis in Mice via Inhibiting Macrophage Inflammatory Response and Regulating the Composition of Gut Microbiota , 2021, Frontiers in Physiology.

[5]  D. Ilchovska,et al.  An overview of the NF-kB mechanism of pathophysiology in rheumatoid arthritis, investigation of the NF-kB ligand RANKL and related nutritional interventions. , 2020, Autoimmunity reviews.

[6]  Jiacan Su,et al.  Targeting actin-bundling protein L-plastin as an anabolic therapy for bone loss , 2020, Science Advances.

[7]  Xiang Xue,et al.  Acacetin Induces Apoptosis in Human Osteosarcoma Cells by Modulation of ROS/JNK Activation , 2020, Drug design, development and therapy.

[8]  Weiyi Chen,et al.  Silencing of miR-138-5p sensitizes bone anabolic action to mechanical stimuli , 2020, Theranostics.

[9]  Kangmao Huang,et al.  Acacetin Suppresses IL-1β-Induced Expression of Matrix Metalloproteinases in Chondrocytes and Protects against Osteoarthritis in a Mouse Model by Inhibiting NF-κB Signaling Pathways , 2020, BioMed research international.

[10]  Xiaojuan He,et al.  Potential Advantages of Bioactive Compounds Extracted From Traditional Chinese Medicine to Inhibit Bone Destructions in Rheumatoid Arthritis , 2020, Frontiers in Pharmacology.

[11]  S. Lim,et al.  Linarin and its aglycone acacetin abrogate actin ring formation and focal contact to bone matrix of bone-resorbing osteoclasts through inhibition of αvβ3 integrin and core-linked CD44. , 2020, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[12]  Xiaoke Zheng,et al.  Acacetin improves endothelial dysfunction and aortic fibrosis in insulin-resistant SHR rats by estrogen receptors , 2020, Molecular Biology Reports.

[13]  W. Haibin,et al.  Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation. , 2020, Pharmacological research.

[14]  Hongbo He,et al.  Positive Effect of Gushukang on Type-H Vessel and Bone Formation , 2020, Frontiers in Cell and Developmental Biology.

[15]  Jinglong Yan,et al.  Nuciferine prevents bone loss by disrupting multinucleated osteoclast formation and promoting type H vessel formation , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  Wei Zhang,et al.  Catalpol suppresses osteoclastogenesis and attenuates osteoclast-derived bone resorption by modulating PTEN activity. , 2019, Biochemical pharmacology.

[17]  B. Mitlak,et al.  Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis , 2019, The Journal of clinical endocrinology and metabolism.

[18]  A. Qian,et al.  Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway , 2019, Molecular and Cellular Endocrinology.

[19]  Shouan Zhu,et al.  Macrophage-lineage TRAP+ cells recruit periosteum-derived cells for periosteal osteogenesis and regeneration. , 2019, The Journal of clinical investigation.

[20]  Huarong Huang,et al.  Circulating miR-338 Cluster activities on osteoblast differentiation: Potential Diagnostic and Therapeutic Targets for Postmenopausal Osteoporosis , 2019, Theranostics.

[21]  Kuo-Hu Chen,et al.  Medical Treatment for Osteoporosis: From Molecular to Clinical Opinions , 2019, International journal of molecular sciences.

[22]  M. Cross,et al.  The Cost of Osteoporosis, Osteopenia, and Associated Fractures in Australia in 2017 , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  Changjun Li,et al.  The association between CD31hiEmcnhi endothelial cells and bone mineral density in Chinese women , 2019, Journal of Bone and Mineral Metabolism.

[24]  P. Lips,et al.  The effect of raloxifene on bone marrow adipose tissue and bone turnover in postmenopausal women with osteoporosis. , 2017, Bone.

[25]  Ping Yang,et al.  Preservation of type H vessels and osteoblasts by enhanced preosteoclast platelet-derived growth factor type BB attenuates glucocorticoid-induced osteoporosis in growing mice. , 2018, Bone.

[26]  Jiacan Su,et al.  18β-Glycyrrhetinic Acid Inhibits Osteoclastogenesis In Vivo and In Vitro by Blocking RANKL-Mediated RANK–TRAF6 Interactions and NF-κB and MAPK Signaling Pathways , 2018, Front. Pharmacol..

[27]  T. Nakashima,et al.  Recent advances in osteoclast biology , 2018, Histochemistry and Cell Biology.

[28]  P. Zhang,et al.  Human type H vessels are a sensitive biomarker of bone mass , 2017, Cell Death & Disease.

[29]  C. Bigot,et al.  α-1 Antitrypsin Inhibits RANKL-induced Osteoclast Formation and Functions , 2017, Molecular medicine.

[30]  L. Hao,et al.  Gα13 negatively controls osteoclastogenesis through inhibition of the Akt-GSK3β-NFATc1 signalling pathway , 2017, Nature Communications.

[31]  M. Bixel,et al.  Blood flow controls bone vascular function and osteogenesis , 2016, Nature Communications.

[32]  Weiguo Zou,et al.  Inactivation of Regulatory-associated Protein of mTOR (Raptor)/Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Osteoclasts Increases Bone Mass by Inhibiting Osteoclast Differentiation in Mice* , 2016, The Journal of Biological Chemistry.

[33]  Yuping Zhang,et al.  Preparative Purification of Bioactive Compounds from Flos Chrysanthemi Indici and Evaluation of Its Antiosteoporosis Effect , 2016, Evidence-based complementary and alternative medicine : eCAM.

[34]  Zhuojing Luo,et al.  Gastrodin: an ancient Chinese herbal medicine as a source for anti-osteoporosis agents via reducing reactive oxygen species. , 2015, Bone.

[35]  W. Grayson Faculty Opinions recommendation of PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. , 2015 .

[36]  Z.-q. Zhang,et al.  Association between dietary intake of flavonoid and bone mineral density in middle aged and elderly Chinese women and men , 2014, Osteoporosis International.

[37]  L. Duong,et al.  PDGF-BB secreted by preosteoclasts induces CD31hiEmcnhi vessel subtype in coupling osteogenesis , 2014, Nature Medicine.

[38]  R. Adams,et al.  Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone , 2014, Nature.

[39]  A. Bode,et al.  The P110 subunit of PI3-K is a therapeutic target of acacetin in skin cancer. , 2014, Carcinogenesis.

[40]  R. Agarwal,et al.  Acacetin Inhibits In Vitro and In Vivo Angiogenesis and Downregulates Stat Signaling and VEGF Expression , 2013, Cancer Prevention Research.

[41]  Soo Young Lee,et al.  Akt Induces Osteoclast Differentiation through Regulating the GSK3β/NFATc1 Signaling Cascade , 2012, The Journal of Immunology.

[42]  Antonia C Hardcastle,et al.  Associations between dietary flavonoid intakes and bone health in a scottish population , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[43]  Ying-Jan Wang,et al.  Acacetin suppressed LPS-induced up-expression of iNOS and COX-2 in murine macrophages and TPA-induced tumor promotion in mice. , 2006, Biochemical pharmacology.

[44]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[45]  S. Mckercher,et al.  Osteopetrosis in mice lacking haematopoietic transcription factor PU.1 , 1997, Nature.

[46]  E. Wagner,et al.  c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. , 1994, Science.